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 1 
Pathways to plausibility – when herbs become pills 
 
Abstract 
Herbal medicine has long been contrasted to modern medicine in terms of a holistic approach to healing, 
vitalistic theories of health and illness and an emphasis on the body’s innate self-healing capacities. At the same 
time, since the early 20th century, the cultivation, preparation and mass production of herbal medicines have 
become increasingly industrialised, scientificised and commercialised. What is more, phytochemical efforts to 
identify and isolate particular ‘active ingredients’ from whole-plant extracts have intensified, often in response to 
increasing regulatory scrutiny of the safety and quality of herbal medicinal products. In this paper, I examine 
whether describing these developments in terms of a biomedical ‘colonisation’ of herbal medicine, as has been 
common, allows us to sufficiently account for the mundane collaborative efforts of herbalists, botanists, 
phytochemists, pharmacologists, toxicologists and clinicians to standardise and develop certain herbal remedies. 
By focusing on recent efforts to industrialise and scientifically develop a ‘western’ (St. John’s Wort) and a 
Vietnamese (Heantos) herbal remedy, I suggest that herbal medicine has come to be not so much colonised as 
normalised, with herbalists, phytochemists and pharmacologists working to develop standardised production 
procedures as well as to identify ‘plausible’ explanations for the efficacy of these remedies. 
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Introduction 
 
In June 1997, the Vietnamese government and the UN Development Programme signed a 
three-year agreement to finance and support a project entitled the “International Scientific 
Development of the Anti-Drug Medication Heantos”. The agreement followed a series of 
reports about this thirteen-plant herbal tonic’s efficacy in the treatment of opiate addiction, 
especially anecdotal news of a trial on 110 morphine-addicted war invalids at the Hoàng Long 
Rehabilitation Centre from 1994 which suggested that following treatment with Heantos, up 
to 80% of these invalids had stopped picking up their free monthly rations of morphine 
provided to them by Vietnam’s health authorities. The herbal tonic had itself been developed 
by traditional herbal practitioner Tran Khuong Ðàn following experimentation during a series 
of self-inflicted addiction withdrawals. Dr. Ha Anh, Head of the Institute of Orthopedics 
Science and Rehabilitation of Wounded Veterans and Invalids, who had followed the 
treatment of the group of invalids concluded in a report to the Ministry of Health that the 
“importance of Heantos is its ability to prevent re-addiction and to appease the patient’s 
craving for drugs” (Vietnam. Institute of Orthopedics Science and Rehabilitation for 
Wounded Veterans and Invalids. 1996). Heantos has since been subjected to two controlled 
clinical trials in Vietnam which have concluded that “Heantos supports the alleviation of 
withdrawal from drug addiction [and] has effects that reduce cravings, reduce paraesthesia, 
reduce symptoms of digestive disorder, recover the patients’ sleep habits and help the patients 
recover their health rapidly as well as clear their minds” (Vietnam. Institute of Chemistry. 
1999: 43). 
 
Around the same time, a full-page article in the health section of the 22 September 1997 issue 
of Time magazine was asking whether St. John’s Wort, a folk remedy made from the plant 
hypericum perforatum, was “Nature’s Prozac?” (Nash and Cray 1997). This and numerous 
other media stories cited a string of recent clinical trials as well as preclinical pharmacological 
experiments that had been carried out in Germany. Especially highlighted was a meta-analysis 
of 23 trials by Linde and colleagues which suggested “there is evidence that extracts of 
hypericum are more effective than placebo for the treatment of mild to moderately severe 
depressive disorders” (1996: 253). And while there has since been a lot of debate about the 
merits of the growing number of clinical trials that have been carried out on St. John’s Wort, 
in the closing years of the 20th century St. John’s Wort became a herbal ‘blockbuster’ 
throughout Europe and America.1 
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Both Heantos and St. John’s Wort have in recent decades been the object of steadily 
increasing scientific scrutiny through phytochemical, pharmacological and clinical research. 
At the same time, production of these two remedies has been industrialised and standardised 
such that both of these ‘natural’ remedies are now available in pill or capsule form. These 
processes have involved collaborations between practitioners of herbal medicine, botanists, 
chemists, pharmacologists, toxicologists and clinicians who have had to negotiate and balance 
quality, safety and batch consistency requirements on the one hand, and an insistence on 
preserving ‘whole plant’ or ‘multiple pot’ extracts (as opposed to isolating and synthesising 
single active ingredients) on the other. 
 
In this paper, I will suggest that accounting for efforts to standardise and industrialise St. 
John’s Wort and Heantos in terms of a ‘scientific colonisation’ or ‘cooptation’ is at best an 
oversimplification. While such descriptions certainly do capture important elements of these 
processes – e.g. phytochemical elucidation of active ingredients, commercial 
commodification of herbal medicine – they do not adequately take into account the complex 
interactions and co-circulations of concepts and practices that constitute the microphysics of 
herbal medicinal product development. 
 
I begin by suggesting that the colonisation hypothesis, which has become common in 
accounts of the scientificisation and industrialisation of herbal medicines (and other forms of 
traditional or alternative medicine), is rooted in Kuhnian incommensurability. I will then go 
on to propose that Canguilhem’s notion of normalisation is better suited when accounting for 
these processes. The bulk of the paper will examine the microphysics of efforts to standardise 
and industrialise St. John’s Wort and Heantos, focusing especially on three key problems: 
how to accurately identify medicinal plant species and record their traditional medicinal uses; 
how to ensure ‘batch-to-batch’ consistency in the production of ‘whole plant’ (in the case of 
St. John’s Wort) and ‘multiple pot’ (in the case of Heantos) extract herbal products; and how 
to establish ‘plausible’ explanations for the suggested efficacy of these treatments. In 
conclusion, I will argue that while the transformation of raw herb materials into pills certainly 
constitutes a normalisation of herbal medicine, this normalising is the result of a complex co-
circulation of herbal, biomedical, phytochemical, pharmacological and botanical concepts and 
practices. 
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From colonisation to normalisation 
 
Throughout the world, there has been a growing interest in herbal medicine in recent decades. 
As ancient as the practice of medicine itself, the use of plants to heal – whether by traditional 
healers, herbalists, apothecarists or pharmacologists who isolate active compounds from plant 
extracts – has been a consistent part of medical practice in all corners of the world. In some 
countries it is estimated that up to 80% of the population continue to rely primarily on 
medicines from plants for their healing needs (WHO 2002). At the same time, while herbal 
medicine has long been a commercialised field of patent medicines and/or medicinal plant 
markets, over the past century or so it has transformed into a highly-technologised, multi-
million dollar industry. Inspired by the pioneer work of German natural products chemists and 
companies in the 1920s and 1930s,2 the industrialisation of medicinal plants into what have 
come to be known as ‘phytomedicines’ or ‘herbal medicinal products’ has developed into a 
global activity with supply chains spanning all the world’s continents. Indeed, the late 20th 
century ‘boom’ in herbal medicine, often cited as evidence of the growing popularity of 
alternative and traditional medicines, refers in large part to rapid rises in the sales figures for 
phytomedicines throughout the 1980s and 1990s (see Gaedcke and Steinhoff 2002; Richter 
2003). 
 
These developments have led a number of scholars to suggest that herbal medicine is in the 
process of being colonised or coopted by ‘western’ biomedicine. For example, in the context 
of traditional Chinese medicine, Ted Kaptchuk has argued that efforts to modernise traditional 
medicine: 
 
are aimed at separating out the effective components of Chinese medicine and introducing them into 
the framework of modern Western medicine… Yet, although this knowledge, with its use of 
traditional herbs and acupuncture, has the veneer of Chinese medicine, the actual application and 
methodology are clearly Western in orientation. The theory of Yin and Yang and other traditional 
concepts are left behind. (1983: 24) 
 
In an article on the “crisis of traditional medicine” in Tibet, Janes argues that traditional 
Tibetan medicine is currently at risk of being “coopted by the medical establishment and 
distributed without concern for (or understanding of) possible iatrogenic consequences” 
(Janes 1999: 1804). In relation to what they see as an increasingly global herbal medicine, 
Jagtenberg and Evans suggest that “with its emphases on mass production, biochemistry and 
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standardization, global herbalism provides an antithesis to the magic of the local...[,] the 
physical and biomedical science’s dismissal of metaphysics, spirituality and value judgments 
marks a basic paradigm divide between traditionally based natural healing modalities and 
biomedicine and the physical sciences” (Jagtenberg and Evans 2003: 328). And finally, Barry 
argues that such a process of scientificisation is complete “when the [alternative] therapy has 
mutated into a medicalised version and divested itself of its alternative philosophy” (Barry 
2006: 2648). 
 
And so it is in contrasting ‘frameworks’, ‘establishments’, ‘paradigms’ or ‘philosophies’ that 
a divide between an authentic traditional herbal medicine and a modernised global herbal 
medicine is posited. There is a clear sense of loss in these accounts – of the traditional, the 
magical, the natural or the metaphysical – and as such they chime well with classic 
modernisation critiques. There are also more or less explicit references to what Thomas Kuhn 
described as “incommensurable ways of seeing the world and of practicing science in it” 
(Kuhn 1962: 4). In Kuhn’s famous view there is an emphasis on the single, ‘winning’ 
paradigm –  “paradigms gain their status because they are more successful than their 
competitors” (Kuhn 1962: 25) – and as such, if two paradigms come into competition (e.g. a 
‘vitalistic’ herbal medicine and a ‘mechanistic’ biomedicine), one of them will eventually 
prevail. And it is exactly in the context of such a competition of paradigms that the 
colonisation hypothesis has been enunciated. 
 
Now, while utilising such a hypothesis can certainly be used to address how particular 
rationalities and practices of validation, standardisation and control in herbal medicine (and 
the various commercial, political or ideological ‘interests’ seen to underpin these) gain their 
authority and legitimacy, its emphasis on a one-sided colonisation makes it very difficult, as 
we will see, to account for often innovative collaborations between herbal practitioners, 
phytochemists and pharmacologists when it comes to standardising and industrialising herbal 
remedies (see also Kim 2006). Instead, what I will show in the following by examining efforts 
to modernise St. John’s Wort and Heantos, is how we might understand these processes in 
terms of a normalisation of herbal medicine by which I mean the appropriation of herbal 
medicine as a distinct object of expert bodies of knowledge which inform and organise 
practices of standardisation, commodification and industrialisation. As we will see: traditional 
or folk knowledge about medicinal plants is considered to be a rich resource yet one about 
which there is, at best, “inconsistent knowledge”, at worst, “profound ignorance”; plants are 
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considered “living laboratories” yet one’s that are notoriously inconsistent in the production 
of active ingredients; and vitalistic theories about how medicinal herbs work have been 
described by some as “incongruent with scientific thought”. As a result, if herbal medicine is 
to be standardised then it must be normalised, where, as Canguilhem has suggested, norms are 
“that which can be used to right, to square, to straighten” and “to normalise, is to impose a 
requirement on an existence, a given whose variety [and] disparity with regard to the 
requirement, present themselves as a hostile” (1989: 238). 
 
There are three distinctive features of the normalisation of herbal medicine that I will 
highlight in the following sections: the first concerns a kind of ethno-scientific taming of the 
countryside; the second concerns attempts to standardise herbal formulas at a molecular, bio-
chemical level; and finally, the third concerns a search for ‘plausible’ mechanisms of action. 
What I will demonstrate throughout this analysis is how so-called ‘vitalistic’, ‘reductionist’, 
‘alternative’ and ‘mainstream’ concepts and practices have all co-circulated within and 
informed practices of ethno-botanical taxonomising, phytochemical standardisation and 
preclinical pharmacological research. 
 
Taming the countryside 
 
The closing decades of the 20th century saw what Parry (2004: 150) has described as a 
“resurgence of interest in collecting biological materials” from the ‘wild’ for medicinal or 
industrial use. There is of course nothing new in the fact that medicinal firms and practitioners 
look to plants in their quest for novel compounds to fight disease (take, for example, 
morphine, aspirin and digitalis), but what has been especially characteristic of this more 
recent resurgence of what has come to be known as ‘bio-prospecting’ is the systematised role 
that traditional knowledge – as handed down or recorded through the generations – has come 
to play in the initial identification and/or screening of suitable plant leads when faced with an 
incredibly lush global bio-diversity.3 In Vietnam, efforts to revitalise Vietnamese herbal 
medicine since the mid 1950s have first and foremost relied on a comprehensive mapping out 
effort that took organised teams of herbalists, botanists and other scientists to the rural areas 
of Vietnam in an attempt to record the experiences and knowledge of traditional practitioners 
(see Wahlberg 2006). Their task was to standardise the different vernacular names of plants 
used by traditional practitioners by using botanical taxonomies as well as to record the most 
common medicinal uses of different plant species. As such, this was in many ways what the 
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19th century botanist John Harshberger, as one of the first, would have called an ethno-botanic 
project – a “study of plants used by primitive and aboriginal people” (1896) – albeit 
unequivocally stripped of Harshberger’s outmoded evolutionary assumptions. To explain the 
launching of the Vietnamese government’s national ethno-botanic programme, Minister of 
Health Pham Ngoc Thach argued that: 
 
The scorn of Western-trained physicians for traditional medicine derives from an erroneous 
conception of science and a profound ignorance of the results obtained by traditional medicine… I 
would like to draw attention to the extreme richness of the vegetal pharmacopoeia of traditional 
medicine. Naturally, one cannot experiment on all these vegetal varieties one after another. The age-
old experience of the people and physicians of the traditional school comes into play here… There is 
a danger of letting this age-old knowledge of medicine disappear rapidly, because if we don’t 
cultivate it those who practice it will have disappeared after ten or twenty years. (Pham 1965: 13-5) 
 
In other words, this was not a national study of how “primitive” peoples used plants, rather it 
was a case of what in more recent times has come to be described as ethnopharmacology and 
ethnopharmacognosy. These latter two ethno-sciences concern the study of all “biologically 
active agents traditionally employed or observed by man” (Heinrich, et al. 2004: 52), 
especially for medicinal purposes. What makes them ‘ethno’ sciences is their systematised 
focus on culturally transmitted traditional knowledge not only as a matter of cultural heritage, 
but also as an important ally in the search for ecologically, industrially and/or medically 
relevant active compounds in the face of the “extreme richness” of the wild. 
 
This was exactly the approach chosen by herbalist Tran Khuong Ðàn as he traversed Vietnam 
from south to north in the 1980s looking for possible leads that could help him in his efforts to 
develop a herbal remedy against addiction. Travelling off the beaten track, Ðàn trekked the 
length of Vietnam’s 2,000 or so kilometres, visiting rural communes and villages where 
opium cultivation and use had been a part of daily life for centuries. In these villages, Ðàn 
sought out traditional herbalists to discuss and exchange ideas on treating opium dependency. 
By the end of the 1980s, Ðàn settled down to digest and organise the experiences and 
knowledge he had amassed during his travels. He also began scouring traditional Chinese and 
modern medical texts to learn as much as he could about addiction as well as methods of 
treatment. It was from this broad base of knowledge, spanning the traditional practices of 
village herbalists and the theoretical underpinnings of Sino-Vietnamese traditional medicine, 
that Ðàn developed Heantos, a thirteen-plant herbal remedy for addiction (Tran 1999). Having 
presented his remedy to health authorities in 1990, Heantos has since undergone a series of 
clinical trials in Vietnam as well as received the support of the United Nations in efforts to 
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further scientifically develop it. One of the first tasks of Ðàn’s collaborators at the Institute of 
Chemistry in Hanoi was to botanically identify and categorise each of the thirteen plants in 
the remedy since, as explained in the United Nations project document: 
 
a common problem in literature [about Vietnamese medicinal plants] is a lack of precise species 
identification (according to latin names denoting species, genus and family). The result is that a 
single species can have up to 20 different local or Vietnamese names in various books, depending on 
the source. It is therefore critical for the standardization of Heantos that each plant is identified and 
taxonomized according to botanical categories. Ethnopharmacognistic studies will also be prepared 
by Vietnamese scientists with the assistance of traditional practitioners throughout Vietnam. 
(UNOPS 1999: annex III) 
 
In many ‘western’ countries, processes of industrialisation and urbanisation are also seen as a 
threat to local knowledge about the healing properties of plants. For example, when a group 
of herbal practitioners, botanists and remedy producers launched an ‘Ethnomedica’ group in 
1999 to ‘Research the Herbal Traditions of Britain’, their rationale for doing so was not unlike 
that of the Vietnamese government’s: 
 
150 years ago Britain was still mainly a rural society. Lives and activities were defined by the 
seasons and everyone knew the names and uses of several common wayside plants. Within two 
generations of the industrial revolution most of the population had moved into cities. As people 
developed an urban lifestyle they lost contact with the land and their practical herbal traditions. Not 
just forgotten but no longer accessible – where was the nearest dandelion, dock, healing tree or 
stream for watercress? …The loss of local knowledge – be it about plants or anything else – is one 
of the side-effects of globalisation and rapidly changing societies. While this issue is recognised in 
the tropics, and is receiving a lot of attention from those concerned with development and the 
conservation of cultural and biological diversity, it is not the case here at home. The UK has long 
been industrialised and ranks among the most developed of regions. Yet studies have shown that 
fragments of knowledge passed down through a long oral tradition still exist among older people. Its 
value increases the more it is lost as time passes. (Ethnomedica 1999) 
 
In the three-year period 2003-2006, over one thousand records of medicinal plant use gleaned 
from interviews and survey cards that had been carried out by a group of 13 researchers as 
well as by the Kew gardens, were collated and organised. Scientists at Kew gardens have also 
been able to use the information gathered as a means of screening potential plant candidates 
for further phytochemical research into therapeutically active compounds. In this way, 
traditional knowledge of the ‘folk’ uses of plants has been instrumental in collaborations to 
collect, organise and investigate plant medicines. 
 
St. John’s Wort (hypericum perforatum) is a case in point. Native to Europe, this plant has a 
long history of medicinal use dating back to the third century BC. In 1630, Italian 
iatrochemist Angelo Sala reported that “St. John’s Wort has a curious, excellent reputation for 
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the treatment of illnesses of the imagination… and for the treatment of melancholia, anxiety 
and disturbances of understanding”. In 1652, one of the ‘founding fathers’ of organised herbal 
medicine practice in Britain, Nicholas Culpeper, classed the very yellow-flowering St. John’s 
Wort “under the celestial sign Leo, and the dominion of the Sun” in his English Physitian. 
And in 1814, Robert John Thornton explained in his Family Herbal how “formerly it was 
supposed, and not without reason, that madmen were possessed of the devil, and this plant 
was found so successful in that disorder, that it had the title Fuga daemonum, as curing 
demoniacs” (cited in Rosenthal 1998: 202). It was exactly with reference to these kinds of 
recorded ‘folk uses’ of St. John’s Wort found throughout Europe that, in 1984, Commission E 
(made up of physicians, pharmacists, naturopathy practitioners, pharmacologists, toxicologists 
and biostatisticians) of the German Federal Institute for Drugs and Medical Devices listed 
“psychovegetative disturbances, depressive moods, anxiety and/or nervous unrest” as possible 
treatment uses for johanniskraut, while noting that “a mild antidepressant action of the herb 
and its preparations has been observed and reported by numerous physicians” (Heilpflanzen-
Welt 2005). Since then, a series of clinical trials have been carried out in Germany, USA and 
the United Kingdom on the efficacy of this plant in the treatment of depression (see Wahlberg 
2008). 
 
And so, in both European and Vietnamese contexts, ethno-sciences have been deployed as a 
specific means to document, organise and archive for posterity the kind of information about 
the medicinal uses of plants that is otherwise seen as at risk of being lost as yet another side 
effect of globalisation and modernisation processes. They have also been deployed to right 
what is considered a “profound ignorance” of the traditional or folk use of plants for healing 
purposes on the one hand, and a “lack of precise species identification” on the other. What has 
made these projects distinct is how the systematised recording of traditional or folk 
knowledge – whether gained through interviews, surveys or historical literature reviews – has 
interacted with botanical, phytochemical and pharmacological research. In both Vietnam and 
western countries such as the UK and Germany, such ethno-scientific projects have involved 
collaborations between traditional herbal practitioners, pharmacologists, botanists and 
phytochemists. 
 
Normalising living laboratories 
 
This paper has been accepted for publication in BioSocieties, and the final (edited, revised and typeset) version of this paper 
will be published in BioSocieties 3(1), 2008 by Cambridge University Press © CUP 2008 
 
 10 
Yet it is not only through an ethno-botanic mapping of the countryside with the aid of field 
notes, literature searches, databases and nomenclatures that the normalisation of herbal 
medicine is taking place. It is also increasingly taking place in chemistry laboratories filled 
with high-tech extraction apparatus, chromatographs and nuclear magnetic resonance 
spectroscopes. It is in these laboratories that the biomass plant samples collected and 
taxonomised by herbalists and ethno-scientists are subject to labour intensive phytochemical 
scrutiny – soaked in extraction solvents, percolated, centrifuged, filtered, dried, partitioned, 
separated, elucidated and finally characterised in their chemical multiplicities. As argued by 
Vietnam’s Health Minister Pham in 1965, plants are great chemists: 
 
Take for instance the medicinal plants… What is the extract of a plant, if not a complex body, the 
product of complicated synthesis? Thus, we have either ready-made medicines or products from 
which we can make higher synthesis, a good part of which process has already been made by those 
living laboratories: the plants… [With] traditional medicine, we have at the same time clinical 
indications to choose the plants for experimentation, and the products of a total or partial synthesis. 
These are the real short cuts offered us by traditional medicine [and] we are working systematically 
in this direction. (Pham 1965: 15) 
 
Notwithstanding such short cuts, the phytochemical partitioning and mapping out of these 
living laboratories is not only necessary for subsequent pharmacological mechanism of action 
research, but is equally necessary for those regulatory initiatives that seek to assure 
consumers, as best possible, that they can expect some kind of standardised quality, not to 
mention safety, of the industrialised herbal products they purchase. For, if there is one thing 
that is characteristic of phytochemistry, it is that it is a science of ranges that seeks to apply 
some kind of consistency to the notoriously inconsistent chemists that plants have been shown 
to be.  
 
Whatever disagreements herbalists and scientists may have over specific mechanisms of 
action as well as concepts used to account for these mechanisms (more on this later), there is 
broad agreement that it is the chemicals found in a plant that have a therapeutically significant 
effect on the body’s physiological functioning when ingested – as put by ‘western’ herbalist 
Simon Mills “it is the nature of the material, the character of the remedies, that is the 
determining factor” (1993: 150). There is also agreement that the amount and quality of 
chemicals found in an extract of a particular plant species is dependent on growing conditions 
(soil, climate, weather conditions, pesticide use), time of harvest (before or after flowering, 
early morning or evening), which part of the plant is used (flower, leaves, stem, bark), 
extraction processes (drying, grinding, boiling, solvent used), as well as storage conditions 
This paper has been accepted for publication in BioSocieties, and the final (edited, revised and typeset) version of this paper 
will be published in BioSocieties 3(1), 2008 by Cambridge University Press © CUP 2008 
 
 11 
(humidity, light, temperature). And while all this can be complicated enough with a single-
plant like St. John’s Wort, it becomes even more complex when working with a thirteen-plant 
herbal remedy like Heantos. 
 
Plants may well be superb chemists, but the exploitation of the chemicals they produce is 
dependent on both the conditions in which they ‘naturally’ produce them and the expertise in 
extracting them from the plants into a form suitable for ingestion – e.g. tinctures, teas or pills. 
And so while sustainable cultivation practices are increasingly being developed with the aim 
of optimising growing conditions for medicinal plant species, phytochemistry has been 
harnessed in the industrialisation of herbal medicine production to help reduce batch-to-batch 
inconsistencies, by breaking plant or remedy extracts down into identifiable single chemical 
compounds that can be isolated, chemically characterised and thereby used as markers in the 
standardisation of herbal products. These optimised cultivation practices and standardised 
chemical markers, it is argued, can then replace a herbalist’s traditional organoleptic 
evaluation of medicinal herbs (taste, smell, texture, appearance) when controlling for quality 
in industrially produced herbal medicinal products. The goal is to ensure “a consistent content 
of therapeutically active constituent(s)… irrespective of the year of harvest and the year of 
production” (Gaedcke and Steinhoff 2002: 16) by standardising production procedures.4 
 
This of course means that in order to be able to standardise a herbal medicinal product 
according to a defined range of therapeutically active constituents, a manufacturer requires 
not only a clear understanding of what is to be standardised (i.e. which chemical compounds), 
but also an understanding of how to ensure more or less controlled cultivation and harvest, of 
appropriate production methods which will not damage or degrade chemical constituents 
excessively during extraction, and of acceptable ranges of constituent content in the final 
plant extract products. These are the specific problems related to the production of whole 
plant extract based products as opposed to single active compound drugs. 
 
St. John’s Wort is a single-plant remedy, even if very often used by herbalists in combination 
with other medicinal plants: “as a nervine, hypericum is usually prescribed with three or four 
other herbs that reflect the individual needs of a patient” (Chevallier 1999: 92). And, not only 
has it become one of the most clinically studied herbal remedies in the world, it has also 
become one of the most phytochemically and pharmacologically analysed plants in the past 
few decades. With a long history of documented medicinal use, as we saw earlier, St. John’s 
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Wort (or hypericum perforatum) has recently been described as a “prolific producer of 
secondary metabolites” (Müller 2005: 5). One of the first of these to have been isolated and 
characterised is the naphtodianthrone hypericin, a red pigment long known for secreting when 
the yellow flowers of St. John’s Wort are squeezed by hand. It has also been found to be the 
culprit in causing hypericism (a disease that leads to potentially lethal photosensitisation) in 
cattle who feed off of the plant, and as a result it has been described as defence agent of the 
plant. Perhaps not so surprisingly then, it was also hypericin that became one of the first lead 
candidates in the phytochemical search for active compounds that might explain its anti-
depressant effects. But hypericum perforatum has since been found to contain many more 
classes of secondary metabolites including phloroglucinols (mainly hyperforin and 
adhyperforin), flavonoids (quercetin, rutin and hyperoside), biflavonoids (biapigenin), 
xanthones, proanthocyanidins (catechin), acid phenols (p-coumric, ferulic and caffeic acids) 
and essential oils (including 2-methyloctane, limonene and myrcene). To date, 
pharmacological studies have singled out hypericin, hyperforin, quercetin and rutin as 
candidate compounds when accounting for St. John’s Wort’s anti-depressant action. 
 
As much as is now pharmacologically known about the active constituents and possible 
mechanisms of action which might account for any experienced anti-depressant effects, it 
remains very difficult to devise standardisation procedures for St. John’s Wort products. To 
begin with, comparisons of the composition of eight key chemical constituents in different St. 
John’s Wort plant specimens have shown variations of as much as 700% in individual 
constituent content measured in micrograms/flowers (Müller 2005: 16). And while the 
German Commission E monographs (published in the 1980s) recommend that products be 
standardised according to a range of hypericin content (0.2-1 mg of total hypericin per 2-4 g 
of herbal drug), more recent research has suggested that hyperforin is more prominent in 
generating anti-depressant pharmacologic action. Moreover, hyperforin has been shown to be 
so chemically unstable (due to a liability to oxidative degeneration) that standardisation 
according to hyperforin content requires very sophisticated and costly extraction techniques. 
With so many variables at play, it is little wonder that an LA Times-commissioned chemical 
analysis of 10 St. John’s Wort brands from 1998 found considerable discrepancies between 
what was promised on labels in terms of hypericin content and what was found to be present 
in sample capsules (three brands contained no more than half the listed amount and four had 
less than 90% of the listed amount) (Monmaney 1998). 
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The challenge for standardising St. John’s Wort then, has become one of balancing a need for 
suitable (preferably therapeutically relevant) biochemical markers that can ensure batch-to-
batch consistency within an accepted range of marker constituents on the one hand, and on the 
other to ensure that the entire spectrum of chemicals particular to St. John’s Wort are present 
in any whole plant extract products made from it. Ensuring that a final herbal drug preparation 
contains a certain constituent within a defined content range, either by adding inert adjustment 
material (e.g. lactose) or blending extract (of the same plant), can ironically enough diminish 
the quality of the original or so-called ‘native extract’, and as a result, it is argued “the initial 
question prior to adjustment should always be, if it is considered more important to administer 
a sufficient quantity of native extract or a defined quantity of the constitutent(s) the extract is 
to be adjusted to” (Gaedcke and Steinhoff 2002: 17). The answer to this initial question is far 
from clear cut with pharmacologists probably inclined to favour the latter and herbalists the 
former. For example, medical herbalist Peter Conway argues that “most herbalists would 
rather use a St. John’s Wort preparation that has a natural balance of constituents, achieved 
through good growing, harvesting and processing, over one that has unnaturally high amounts 
of one element, as in many standardised products” (2003: 21). Bearing in mind that ‘natural’ 
variation in this “natural balance of constituents” can be considerable, Conway does suggest 
that “it is possible to check the quality of herbal preparations and ensure that there are the 
right amounts of a broad spectrum of the desirable chemicals present in the product without 
artificially altering their relative amounts” (ibid.).5 And so the problem remains of just how to 
define what is meant by the “right amounts”, a task that invariably will require some kind of 
‘normal spectrum’ marker profiles against which batches can be checked or ‘quality 
controlled’. 
 
As already mentioned, herbal practitioners have in the past relied extensively on organoleptic 
evaluations of quality, either as they gathered their starting materials from the wild or upon 
purchasing them from commercial suppliers or at medicinal herb markets. However, new 
regulations in both Vietnam and the European Union increasingly require laboratory-
confirmed quality assurances for especially industrially produced herbal products, but also for 
starting materials. And it is in these practices of quality assurance that control profiles based 
on chromatographic ‘fingerprints’ have become crucial. By using thin layer (TLC), gas liquid 
(GLC) and high performance liquid (HPLC) chromatography methods, a plant extract can be 
broken down into its various chemical constituents, appearing as either bars on a TLC 
chromatogram or peaks on GLC and HPLC chromatograms. And just as the fingerprints from 
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a crime scene can be checked against a database of past suspects for a match, so too can the 
chromatograms from a new batch of herbal medicine extract be checked against constituent 
control ‘profiles’ to ensure a standard batch-to-batch consistency. For, once 
chromatographically separated, chemical constituents can be phytochemically identified using 
nuclear magnetic resonance spectroscopy or mass spectrometry, which allow for three-
dimensional structure elucidation of an individual molecule of the chemical constituent under 
scrutiny. The goal being to identify suitable marker compounds unique to the medicinal herb 
in question, which can then be used to build chemical reference profiles based on norms of 
purity and content. 
 
It is also these isolated chemical constituents which can then be individually assayed for 
possible pharmacologic actions (something we will return to later in this article), and thereby 
classed into groups of either therapeutically active constituents (i.e. those “with known 
therapeutic activity”), active constituents (i.e. those “which contribute to therapeutic 
efficacy”), or marker substances (i.e. those “which, according to the state of scientific 
knowledge, do not contribute to therapeutic activity… [yet] are suitable for identification tests 
and assay (e.g. batch-to-batch control)”) (Gaedcke and Steinhoff 2002: 22-3). Hence, the 
standardisation of St. John’s Wort products today is carried out using not only quantitative 
content ranges for hypericin and/or hyperforin (expressed in terms of milligrams per daily 
dose) which have been identified as pharmaceutically relevant constituents, but also 
qualitative chromatographic standards which reflect an aim to ensure that an extract contains 
the plant’s ‘full spectrum’ of constituents in relevant amounts. 
 
Now, as we can see, the challenge of standardisation in the case of St. John’s Wort has been a 
time-consuming, costly and technically sophisticated affair. So much so that one can only 
imagine the magnitude of such a task when presented with a mixed extract containing all of 
thirteen different plants, such as Heantos. When Tran Khuong Ðàn approached health 
authorities in Vietnam with his herbal mixture for the treatment of drug addicts in 1990, his 
remedy came in the form of a dark, rather earthy-tasting syrup, the result of a complex 
process of cutting, drying, boiling and mixing. As already highlighted, Ðàn had spent many 
years learning from the experiences of fellow traditional practitioners, by travelling 
throughout the countryside collecting over one hundred home-made recipes for treating 
opium addiction in the 1980s. On the basis of this gathered knowledge combined with 
information gleaned from classic medicinal texts (most of which were written in Chinese and 
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Nôm6), Ðàn began experimenting with various herb combinations and preparation methods. It 
was at this time, during the late 1980s, that Ðàn decided to intentionally addict himself to 
opium in order to personally evaluate the different remedy batches. He would later argue that 
“the only way I could test my medication was to experience the torture of withdrawal for 
myself” (Tran 1999). And so, through a period of two years, Ðàn would undergo a series of 
self-inflicted withdrawals, all the while experimenting on himself with the different mixtures 
he would devise. Ðàn’s final choice fell on a set of thirteen plants and a complex processing 
protocol which together would produce a herbal remedy for treating addiction with some kind 
of consistency. It was using this home-brewed syrup that the trial on war invalids described 
above was carried out in the early 1990s. 
 
Starting in 1995, however, Tran Khuong Ðàn donned a white laboratory coat in an interesting 
collaboration with some of Vietnam’s top chemists at Hanoi’s Institute of Chemistry, as part 
of a UN-sponsored effort to standardise and further develop Heantos. Whereas it was the 
botanists, ecologists and chemists who had been sent out to the Vietnamese countryside on 
ethno-scientific missions to liaise with traditional herbal practitioners in the past, in this 
collaboration, a traditional herbal practitioner was invited to join chemists in their 
laboratories, to assist them in their efforts to identify and characterise the chemical 
constituents that may be contributing to the therapeutic effects purported to have been 
witnessed in by now some 9,000 or so patients who have been treated with Heantos in 
Vietnam. To be sure, Ðàn’s presence in the laboratory has been far from cosmetic, rather his 
detailed knowledge of the medicinal properties of each of the plants in Heantos has been 
instrumental in the transformation of Heantos from its original syrup form into ‘standardised’ 
capsules. From the identification of the particular medicinal plant species to guidance on the 
best methods for extracting therapeutic constituents from these plants, Tran Khuong Ðàn has 
worked closely with Professor Tran Van Sung over the past decade as a partner in the 
laboratory. The Institute of Chemistry has in turn, for reasons which will become clear, 
enlisted their long time partners at the Leibniz Institute of Plant Biochemistry in Halle, 
Germany, to help with ongoing efforts to chemically characterise Heantos, with the ultimate 
aim of accounting for its therapeutic action. 
 
There have been two key objectives in the further scientific development of Heantos since the 
mid 1990s. The first has been to transform Heantos into a stable, so-called ‘multiple pot’ 
herbal extract. That is to say, to take the first step towards standardisation by introducing 
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reproducible extraction procedures, by building on Tran Khuong Ðàn’s original, perhaps 
more crude, methods of extraction. In October 1997, the first results of the collaboration 
between Ðàn and the Institute of Chemistry came in the form of the first batch of Heantos dry 
extract capsules. To make things more practicable, Ðàn and Sung had agreed to divide the 
plants into three groups, each with a specific therapeutic function as determined by Ðàn. Each 
of these three groups of plants was then processed into three individual dry extracts, which 
were subsequently manufactured into Heantos 1 (for withdrawal), Heantos 2 (a sedative to 
help patients sleep) and Heantos 3 (to help prevent relapse after withdrawal by keeping 
cravings at bay) capsules. 
 
The second key objective in the Institute of Chemistry’s efforts to further scientifically 
develop Heantos has been to phytochemically characterise each of the thirteen plants included 
in the original herbal syrup, in much the same way that St. John’s Wort has been, so as to be 
able to standardise production procedures. And seeing as this task is a technology-intensive 
affair (some of which is not available in Vietnam), the Institute of Chemistry called upon their 
long time partners at one of Europe’s most advanced plant biochemistry institutes in Halle to 
assist them in this effort. In the period May 2000 to March 2006, Vietnamese and German 
chemists joined forces to characterise the chemical constituents found in each of Heantos’ 
thirteen plants. Starting with literature reviews in Chinese, Vietnamese, as well as 
international bibliographic databases to map out existing studies on the plants in question, the 
scientists employed chromatographic methods (thin layer, middle performance liquid and 
high performance liquid chromatography) to isolate pure compounds from Heantos 
components, and then infrared, ultraviolet, mass, and nuclear magnetic resonance 
spectroscopy to structure-elucidate these compounds. The goal of these initial phytochemical 
efforts was “not to pursue the isolation of single bio-active principles and their synthesizing”, 
but rather “to contribute to the optimisation of the efficacy of Heantos, to its development as a 
standardised product and to the scientific explanation of the effectiveness of a medication, 
which has its origin in traditional medicine” (Vietnam. Institute of Chemistry. 2001: 5-6). 
 
These efforts were given renewed importance in 2001, when the German government required 
that analytical techniques for confirming the declared contents of Heantos be developed as a 
precondition for a randomised controlled trial with Heantos that was due to take place at the 
University of Essen. As a result, not only has the Institute of Plant Biochemistry assisted 
fellow Vietnamese chemists with their isolation and characterisation work using nuclear 
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magnetic resonance spectroscopy, they have also embarked on an unprecedented effort to 
develop analytical techniques using mass spectrometric multiple reaction monitoring that 
would allow for the identification of marker compounds from all thirteen plants in what had 
now become a single dry Heantos extract. A further outcome of the initial phytochemical 
analyses of the Heantos components has been a rethinking of the strategy of extraction that 
had initially been developed at the Institute of Chemistry in Hanoi to produce Heantos 1, 2 
and 3 capsules. On the basis of the initial literature reviews and chemical characterisations of 
the Heantos plants, Tran Khuong Ðàn and Tran Van Sung decided to re-group the plants for 
extraction, this time not in accordance with therapeutic aims, but rather according to the most 
prominent group of secondary metabolites found in each of the plants. In doing so, they 
argued that the amounts of extracted active ingredients could be enhanced as different types 
of constituents require different extraction methods to optimise yields. Using this new 
strategy of extraction, the thirteen plants7 were again divided into three groups that were then 
submitted to three different extraction methods, using particular solvents, temperatures and 
extraction times for each group. The resulting mixtures were then evaporated into three 
different pastes or powders, which were mixed together before a final evaporation was carried 
out, resulting in a final ‘multiple pot’ powder extract. This was subsequently manufactured 
into what are now known as Heantos 4 capsules. As a result, therapeutic concerns have 
become more a matter of adjusted Heantos 4 dosage regimens during the course of treatment 
than of using different Heantos capsules at different stages (Tran 2004). 
 
We will recall how complex it can be to develop ‘fingerprint’ control profiles which are 
faithful to the ‘normal full spectrum’ of constituents in a single plant like St. John’s Wort. As 
put by Professor Ludger Wessjohann of the Institute of Plant Biochemistry, “analysing an 
extract which contains thirteen different plants is like being asked to identify an individual 
fingerprint from a single card which has had hundreds or even thousands of fingerprints 
messily jammed on top of each other” (Wessjohann 2005). A high performance liquid 
chromatogram of a single-plant extract will often produce relatively sharp peaks indicating 
the presence of some of the more predominant metabolites in the plant, while a similar 
chromatogram of a Heantos 4 extract gives a much smoother curve as all the different 
metabolite peaks ‘hide’ by blending and blurring into each other – an effect that a single bio-
active compound approach seeks to avoid by breaking an extract down into the lowest 
possible chemical denominators and taking it from there. Nevertheless, as scientists in 
Germany and Vietnam have been committed to working towards a standardisation of the 
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entire Heantos mixture, the Institute of Plant Biochemistry has had to enter uncharted 
territories in their efforts to develop analytical methods that would allow for the confirmation 
of the presence of all thirteen plants in a Heantos 4 extract in accordance with German 
national requirements. 
 
Since it was much too early in late 2005 to form any conclusions about what might be the 
most important therapeutically active constituents, not to mention contributing active 
ingredients in Heantos, the Institute of Plant Biochemistry has instead focused on searching 
for unique marker substances from each plant which could be reproducibly identified in the 
final Heantos 4 extract as a means to confirm their presence in the extract. Chemists at the 
Institute of Drug Quality Control in Hanoi had already successfully identified six out of the 
thirteen plants by comparing high performance liquid chromatographs of Heantos 4 extracts 
against control profiles of the thirteen plants, but HPLC data was not sufficiently detailed for 
identifying the remaining seven. This task would require submitting Heantos 4 extract to the 
kind of technology-intensive structure elucidation spectroscopy that is usually reserved for 
single compounds. Although the resulting data might be described in terms of a lot of ‘noise’ 
resulting from the thousands of compounds in Heantos 4 extracts, it nevertheless became 
possible to search for particular patterns in the resulting hydrogen atom spectrums, which 
might then be used to confirm the presence of previously identified unique marker substances 
from each of the plants in question. 
 
Searching for plausibility 
 
Much of the debate and controversy surrounding traditional, complementary and alternative 
medicines, such as herbal medicine, revolves around the question of whether or not they work 
in the treatment of certain conditions (see Wahlberg 2008). In the cases of St. John’s Wort 
and Heantos, notwithstanding considerable clinical scrutiny, there certainly remain a number 
of open questions as to whether or not they ‘work’ in the treatment of depression and 
addiction respectively.8 Nevertheless, as we have seen, there have been sufficient indications 
to convince chemists and pharmacologists to pursue research into the chemistry and 
pharmacology of these plants, not only to assist efforts to standardise the production of these 
remedies as I have shown above, but also to search for pharmacologically plausible 
mechanisms of action. This search for plausibility in explanations for efficacy is the final 
route of normalisation that I will be accounting for in this paper. 
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Tran Khuong Ðàn has provided a complex account of the mode of action of Heantos in terms 
of a therapeutic restoration of the balance of Yin-Yang and the five basic elements in an 
addict’s body using relevant medicinal plants: “it is by rebalancing Yin and Yang in the body 
and not by suppressing individual withdrawal symptoms that these symptoms will disappear 
of their own” (Tran 1999). At the same time, he has also described how, while developing 
Heantos, he chose particular plants for his remedy with the specific aim of addressing a 
“chronic shortage of drugs in the brain” by normalising the regulation of endorphins in a 
detoxified addict (ibid.). Indeed Ðàn has argued that: 
 
while traditional medicine was developed over thousands of years, certain aspects still need to be 
explained scientifically. And so, it tends to be regarded as superstition. Using science to throw light 
on traditional medicine is imperative. (cited in Impact 2000) 
 
Similarly, medical herbalist Andrew Chevallier has characterised St. John’s Wort as a 
‘nervine’, “having a restorative and tonic or relaxant effect on the… battered nervous and 
endocrine systems of people suffering from nervous exhaustion, depression, nerve damage, 
long-term emotional stress, anxiety, and the like”, while also suggesting that it “markedly 
increases, to a significant degree, serotonin, noradrenaline and dopamine levels within the 
synapse, and seems to enhance the tranquilising activity of GABA and benzodiazepine – all 
of which are involved… in the onset or maintenance of depression” (1999: 91, 47). And 
medical herbalist Peter Conway argues that “to understand what St. John’s Wort does exactly, 
we need first to have a basic understanding of the special chemicals (called neurotransmitters) 
that are involved in nervous system functions” (2003: 23). 
 
Perhaps the by now very familiar anthropological argument that patients notoriously lack 
loyalty to any one particular coherent explanatory framework should be extended to 
practitioners as well. At any rate it does not appear that these herbal practitioners have any 
trouble maintaining different explanations for efficacy in their accounts for how these 
remedies work. Should our conclusion be that these herbal practitioners have been ‘colonised’ 
and that they have lost touch with a more authentic traditional herbal medicine? If so, it does 
not appear that this colonisation has required these practitioners to discard 
‘incommensurable’, vitalistic explanations – i.e. explanations which are considered by some 
as “not congruent with current scientific thought” (Great Britain. Parliament. House of Lords. 
Select Committee on Science and Technology. 2000: 4.31) – of how these herbal remedies 
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work. Whatever incommensurabilities are at stake, there seems to be plenty of room for 
cooperation, even if conclusions are not shared at the end of these collaborations. 
  
What is clear from experiences with St. John’s Wort and Heantos is that ‘plausibility’ is 
something that is to be found through a molecular mapping of the pharmacokinetic and 
pharmacodynamic pathways that individual chemical compounds found in Heantos and St. 
John’s Wort follow as they are absorbed into and then disposed of by the body, and not in 
explanations which invoke meridian-based pathways of Yin-Yang rebalancing, the vital 
nourishing of nervous systems or the maintaining of vital rhythms in the organs of the body. 
Yet, at the same time, as we will see, these differing ‘languages of life’ have nevertheless co-
circulated in recent efforts to unravel pharmacological mechanisms of action. In particular, 
the concept of ‘synergy’ has been central to the search for plausibility, a concept that has been 
described as both ‘vitalistic’ and ‘mechanistic’. 
 
In an article reviewing ten years’ worth of pharmacologic research into the mechanisms of 
action of St. John’s Wort in the treatment of depression, Butterweck (2003: 558) concludes: 
 
Herbal medicines are complex mixtures of more than one active ingredient. Therefore, 
pharmacological work is complicated by the fact that active compounds are often unknown. Further, 
synergistic or antagonistic effects of the different compounds cannot be excluded… Today, several 
compounds from different structural groups and with different mechanisms of action seem to be 
responsible for the observed antidepressant efficacy of St. John’s Wort. Based on recent research, it 
seems likely that flavonoids, hyperforins and hypericins contribute to the antidepressant efficacy… 
[Yet] the mechanism of action of the plant is still not fully understood. Our understanding of the 
mode of action of St. John’s Wort is complicated by the fact that the molecular basis of depression 
itself is still unclear. 
 
It is amidst this complex of chemical compounds, their synergistic and antagonistic 
interactions, and their separate yet supplementing pathways of pharmacologic action that 
explanations for St. John’s Wort’s efficacy in treating a complex condition like depression has 
been sought after with the help of in vitro receptor binding assays on the compounds found in 
hypericum extract, ex vivo studies of rat brains following chronic administration of St. John’s 
Wort, and in vivo efficacy studies using animal models of depression. The very first 
pharmacologic investigations from the early 1980s (Suzuki, et al. 1984; 1981) had 
unsurprisingly focussed on one of the plant’s most conspicuous chemical constituents, 
mistakenly attributing hypericin (rather than the whole plant extract) monoamine oxidase 
inhibiting properties.9 Butterweck et al. (1998) have argued that hypericin does nevertheless 
generate anti-depressant activity, but, interestingly, seems to require the services of 
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procyanidins (also present in whole plant St. John’s Wort extract) in increasing its water 
solubility and thereby its bioavailability. Most recently, hyperforin (a phloroglucinol unique 
to hypericum) has emerged as another prime candidate when accounting for the therapeutic 
efficacy of St. John’s Wort, this time as an inhibitor of the synaptosomal reuptake of 
neurotransmitters (Chatterjee, et al. 1998; Müller, et al. 1998). Pharmacologic studies of 
hyperforin have suggested that St. John’s Wort is a broad spectrum reuptake inhibitor of not 
only serotonin and noradrenaline but also dopamine, GABA and L-glutamate. The precise 
mechanism of inhibition is yet to be established conclusively, but studies suggest that 
inhibition is noncompetitive – i.e. St. John’s Wort “does not inhibit neurotransmitter uptake 
via direct interaction with the specific binding sites of the neurotransmitter transporter 
molecules” (Müller 2005: 38). Instead, the inhibitory mechanism of St. John’s Wort has been 
hypothesised in terms of its elevation of intracellular sodium concentration, which in turn 
reduces the drive for neurotransmitter accumulation within the cell. Studies have also 
suggested that St. John’s Wort extract might reduce stress-induced increases in gene 
transcription as another possible pathway of anti-depressant action. 
 
Tying up the major results to have come out of this flurry of research, a number of reviews of 
the pharmacology of St. John’s Wort have been published in the past couple of years. And 
although one might well have expected these reviews to pinpoint a single compound as 
responsible for its efficacy as an antidepressant treatment, conclusions seem instead to point 
towards a “synergistic” effect where multiple compounds act along multiple pathways with 
multiple targets contributing to a combined efficacy (Butterweck 2003: 554; Müller 2005: 26, 
81). Interestingly, it is also hypothesised that it is this synergistic combined effect that 
accounts for St. John’s Wort’s favourable safety profile (in comparison with standard 
antidepressant treatments), as, rather than exhibiting a single, highly potent antidepressant 
activity, St. John’s Wort extract exhibits multiple lower potency antidepressant activities that 
when combined, it is argued, can match standard antidepressants in efficacy while sparing the 
patient from side effects. 
 
Nevertheless, it is important to underscore that ‘synergy’ between the various active 
compounds found in St. John’s Wort is understood in different ways in the pharmacological 
literature. On the one hand, synergistic effect is described in a strictly “additive” sense 
(Butterweck 2003: 554) whereby “various relatively weak effects result in the overall 
pharmacological effect” (Gobbi and Mennini 2005: 26), while on the other, it is suggested 
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that “the pharmacological effects of the single constituents differ when given alone or in 
combination with other constituents, indicating that the extract is more than the sum of the 
single compounds” (Noldner 2005: 81). This latter view is congruent with that found in many 
texts by herbal practitioners who suggest that “the whole plant is much more than the sum of 
its parts” (Chevallier 1999: 17; see also McIntyre 1988: 53; Mills 1993: 263). Whatever the 
understanding of ‘synergy’, what pharmacological efforts to account for the pathways of 
action of St. John’s Wort have shown is that it is an over-simplification at best to suggest that 
all pharmacologists insist on breaking down plant extracts “by isolating and synthesising the 
[single] active principles of herbs to use as drugs” (McIntyre 1988: 53). Just as Watt and 
Wood (1988) have argued that there is no monopoly on holism in a clinical context, we might 
say that neither is there one in a preclinical context. 
 
Compared to St. John’s Wort, much less preclinical mechanism of action research has been 
carried out on Heantos to date. It is only very recently that the Institute of Plant Biochemistry 
in Halle has begun bio-assay testing the biological activity of the many compounds found in 
the multiple-pot Heantos 4 extract. For this assay testing, the Institute of Plant Biochemistry 
in Halle has enlisted a polymerase chain reaction-based gene expression profiling method 
trademarked by the German biotech company Biofrontera as “Digital Expression Pattern 
Display”. This method has been specifically developed “for the purposes of elucidating 
pathology pathways of major brain diseases, of analysing the target profiles of drugs presently 
applied or in development, and of identifying novel targets for drug action” (Maelicke and 
Lubbert 2002: 283). 
 
And so we can see how a search for plausibility has brought initial vitalistic explanations of 
the efficacy of St. John’s Wort and Heantos (in terms of a nourishing of nervous systems or 
rebalancing of vital energies) into a so-called “pre-clinical” pharmacological realm, where 
balancing and regulating refer to genes, neurochemicals, synapses and receptors. That is to 
say when it comes to explanations of how St. John’s Wort and Heantos work, plausibility 
relies on a language of receptor regulation, neurotransmission and modulation and not a 
language of meridians, energy flows and vital rhythms. It might well be tempting to describe 
this in terms of a ‘colonisation’ of herbal medicine by biomedicine, yet as we saw such a one-
sided account misses out on the numerous interactions between herbal and modern medicine 
that, for example, have resulted in scientists resisting the classic ‘single compound’ approach 
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that pharmacologists are often charged with blindly following as well as in differing 
understandings of ‘synergy’. 
 
Conclusion 
 
What I have shown in this paper is that insisting on the colonisation hypothesis makes the task 
of accounting for the emergence of Heantos and St. John’s Wort as two herbal treatments for 
addiction and depression respectively in the 1990s very difficult. At best, one would have to 
conclude that these two herbal remedies are but the latest casualties of modernity’s incessant 
drive to rationalise, commodify, industrialise and colonise ‘nature’. What I have described as 
a normalisation of herbal medicine would no doubt be read by some as nothing short of such a 
‘scientific colonisation’, an erosion of tradition, a loss of magic. If this is the case, then how 
should we understand the efforts of doctors, scientists and traditional practitioners alike to 
standardise and industrialise herbal medicine into capsules and pills? And how should we 
read the literature by herbal practitioners on St. John’s Wort and Heantos which easily 
incorporates both vitalistic concepts and neuropharmacologic findings into accounts of the 
efficacy of these remedies in the treatment of depression and addiction? Have they all been 
co-opted, forced to ‘sell out’ in the face of market pressures or biomedical ‘interests’? And 
are St. John’s Wort and Heantos all the worse for it? 
 
Whatever the verdict and notwithstanding the antagonisms that clearly do divide herbal 
medicine and modern medicine, there does seem to be some kind of common ground at stake 
– how to demonstrate, account for, consistently ensure and even improve the efficacy of St. 
John’s Wort and Heantos. This is not to say that there has been full agreement on how to 
address these central problems, or indeed on whether or not these treatments have any 
therapeutic merit whatsoever; this much should be clear from the foregoing analysis. Yet, just 
as there can be disagreement between herbal and modern medicine practitioners, so too can 
there be diverging hypotheses amongst herbal practitioners or between pharmacologists or 
clinicians. Moreover, just as pharmacological concepts of biological ‘regulation’ have 
informed accounts of the efficacy of herbal medicines, so too have herbal concepts of 
‘synergy’ or ‘polypharmacy’ informed possible routes of pharmacological investigation and 
standardisation. The importance of producing full spectrum extracts of St. John’s Wort, as 
well as sticking to a multiple pot extract of Heantos (rather than breaking Heantos down into 
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each of its plants), has been underscored rather than undermined in German and Vietnamese 
pharmacology and chemistry laboratories. 
 
As we have seen then, the normalisation of herbal medicine via an ethno-botanical taming of 
the countryside, a phytochemical effort to molecularly characterise and standardise herbal 
remedies into capsules or pills and a pharmacological search for plausible mechanisms of 
action has relied on an assemblage of concepts (synergy, balance, regulation), objects (plants, 
extracts, pills, active ingredients, spectroscopes) and norms (plausibility, natural balance of 
constituents, batch-to-batch consistency) which taken together can account for and 
standardise the workings of the ‘living laboratories’ that plants have been shown to be. 
Normalisation has addressed the ignorance, imprecisions, inconsistencies and incongruencies 
that are seen to surround herbal remedies by attempting to right or square these. And rather 
than resulting in some kind of finality or certainty, the process continues to be surrounded and 
informed by contestation and rectification. 
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Endnotes
                                                 
1
 The sales figures for the US market were spectacular in the final years of the 1990s, with some estimates 
suggesting that sales jumped 190% from $48 million in 1997 to $140 million in 1998. In Europe, sales figures 
for 1998 have been estimated at $6 billion. And in Britain, an estimated 2 million people were using St. John’s 
Wort in 2000. Ironically enough, increased attention to St. John’s Wort also resulted in a number of media 
reports suggesting that St. John’s Wort negatively interacted with a number of commonly used conventional 
drugs, which resulted in an almost immediate sales decline in Europe and America (Blumenthal 1999; Kelly 
2001; Lawson 2000). 
2
 See Timmermann (2001) and Kenny (2002) for discussions on how companies like Madaus, supported by the 
National Socialist regime took the lead in researching and industrially developing herbal medicines. 
3
 Of the world’s 250,000 or so species of higher plants only 6% have been investigated for their biological 
activity (Heinrich, et al. 2004: 289). 
4
 As Gaedcke and Steinhoff (2002) point out, it should be underscored that in far from all herbal plants and 
remedies have therapeutically active constituents been pharmacologically identified. For these herbal medicinal 
products, ‘standardisation’ refers to the implementation of standardised Good Manufacturing Procedures which 
can ensure some kind of batch-to-batch consistency where marker compounds are not necessarily therapeutically 
active. 
5
 Mills concurs arguing that “although there is variability, it is within workable limits, and quality control can 
reduce it even further” (1993: 262). 
6
 Nôm is a script developed around the 10th century by using and modifying Chinese characters to write 
Vietnamese. 
7
 Importantly, since the plants of Heantos are not at this stage cultivated, the chemists rely on Tran Khuong 
Ðàn’s organoleptic evaluation of plant samples before carrying out standard analysis against existing control 
profiles. 
8
 For example, in a British Medical Journal editorial, De Smet and Nolen wrote of the trials included in Linde et 
al.’s (1996) meta-analysis “although promising, these studies are not sufficient to accept the use of hypericum 
extract in major depression when judged against the criteria of the European Union guidelines for regulatory 
evaluation of antidepressants” (De Smet and Nolen 1996: 242) and the largest randomised controlled trial carried 
out on St. John’s Wort to date concluded that St. John’s Wort was less effective than placebo and standard anti-
depressants in the treatment of major depression (Davidson, et al. 2002). And the UN Drug Control Programme 
concluded in 2001 that “there does not appear to be any evidence that Heantos is more effective than any other 
products available for a similar ‘treatment’” (UNDCP 2001). 
9
 It has been suggested that the hypericin samples used by Suzuki et al. were not ‘pure’, but contained at least 
20% of other constituents, notably flavonoids, which would explain why subsequent experiments have 
confirmed monoamine oxidase inhibiting properties of full plant extracts but not of purified hypericin 
(Butterweck 2003: 541-44). 
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